Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. November 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer

SAN DIEGO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
22. November 2016 16:05 ET | Quelle: Otonomy, Inc.

Otonomy to Present at Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
03. November 2016 16:13 ET | Quelle: Otonomy, Inc.

Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
02. November 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Announces Assignment of J Code for OTIPRIO®

SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
27. Oktober 2016 16:05 ET | Quelle: Otonomy, Inc.

Otonomy to Report Third Quarter 2016 Financial Results and Provide Corporate Update

SAN DIEGO, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
07. Oktober 2016 08:00 ET | Quelle: Otonomy, Inc.

Otonomy Holds Investor and Analyst Day and Provides Corporate Update

SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
04. Oktober 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes

SAN DIEGO, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
29. September 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy to Host Investor and Analyst Day on October 7, 2016

SAN DIEGO, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
15. September 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes

SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
13. September 2016 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting

SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...

Vorherige Seite

Nächste Seite